Physician profile
Bilal Sitwat
NPI 1497982979
$42,365.05
in general payments reported to CMS, 2019-2025
11 companies · $29K in 2025
The $29K reported for 2025 was more than what 96% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.16 · 2020: $29.11 · 2021: $247 · 2022: $55.00 · 2023: $4,931 · 2024: $7,671 · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Consulting Fee: $8,345 · Travel and Lodging: $6,890 · Food and Beverage: $2,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,758.00 |
| Consulting Fee | $8,345.25 |
| Travel and Lodging | $6,890.21 |
| Food and Beverage | $2,017.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $39,546.05 | 2023-2025 | Valtoco |
| Ceribell, INC. | $1,733.75 | 2025 | Pocket Eeg Device |
| Ucb, INC. | $270.06 | 2020-2025 | Briviact, Fintepla, Nayzilam |
| Neurocrine Biosciences, INC. | $246.67 | 2021 | |
| Jazz Pharmaceuticals INC. | $155.68 | 2023-2025 | |
| Livanova USA, INC. | $148.71 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Sk Life Science, INC. | $125.00 | 2024 | Xcopri |
| Aucta Pharmaceuticals, INC. | $60.97 | 2025 | Motpoly Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $55.00 | 2022 | |
| Supernus Pharmaceuticals, INC. | $23.16 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bilal Sitwat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.